The potential roles of osmotic and non-osmotic sodium handling in mediating effects of SGLT2 inhibitors on heart failure

Type 2 diabetes (T2D) is an established risk factor for ischemic cardiovascular disease (CVD) and heart failure (HF).(1) The risks of ischemic CVD and HF are increased with albuminuria and/or impaired kidney function. Although in recent decades cardiovascular outcomes have improved for adults with or without T2D, reducing the burden associated with HF by treating classical cardiovascular risk factors has proven to be difficult and thus remains a major public health priority.(2) Accordingly, the introduction of sodium-glucose cotransporter (SGLT) 2 inhibitors offers promise to mitigate cardiorenal disease in people with or without T2D.

Source: Journal of Cardiac Failure - July 17, 2021 Category: Cardiology Authors: Petter Bjornstad, Peter J. Greasley, David C. Wheeler, Glenn M. Chertow, Anna Maria Langkilde, Hiddo J.L. Heerspink, Dani ël H. van Raalte Source Type: research